Pfizer has today lifted its annual profit forecast, banking on cost cuts, a smaller-than-feared drop in sales for its Covid antiviral treatment and strong demand for pneumonia vaccine.
Shares of the US drugmaker have lost 11% of their value this year on worries over its growth after the pandemic as billions of dollars in Covid vaccine and treatment sales evaporated.
The drugmaker has responded with a $43 billion purchase of cancer drugmaker Seagen, a $4 billion cost-cut plan and internal restructuring.
Pfizer reiterated its annual revenue forecast of $8 billion from the sale of Covid-19 shot Comirnaty and anti-viral treatment Paxlovid.
Revenue from Comirnaty, for which it partners with Germany's BioNTech, continues to perform consistently with its expectations, Pfizer said.
However, first-quarter sales from the vaccine came in at $354m, missing analysts' average estimate of $496.5m.
Pfizer expects about 90% of vaccine sales to occur in the second half, mostly in the fourth quarter.
Sales of Paxlovid stood at $2.04 billion for the quarter, beating analysts' expectations of $762.5m.
"Paxlovid revenues in the quarter indicate a successful transition into the commercial marketplace," CEO Albert Bourla said.
Its market-leading pneumonia family of vaccines, sold under the brand name Prevnar, brought in sales of $1.69 billion, beating estimates of $1.66 billion.
Pfizer last year renegotiated a contract, allowing the US government to return unused Paxlovid inventory. It recorded a $771m favourable adjustment in the quarter related to the US government return of some treatments.
The company expects adjusted earnings per share of $2.15 to $2.35 in 2024 compared with a prior forecast of $2.05 to $2.25.
It posted an adjusted profit of 82 cents per share, while analysts on average were expecting it to earn 52 cents, according to LSEG data.
